Article de revue
Efficacy and long-term safety of a dengue vaccine in regions of endemic disease
A recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) has been assessed in two phase 3 randomized efficacy trials involving more than 31,000 children between the ages of 2 and 14 years in the Asian
Auteurs
Langues
- Anglais
Année de publication
2015
Journal
NEJM
Type
Article de revue
Catégories
- Vaccins et dispositifs d'administration
Maladies
- Dengue
Pays
- Thaïlande
Mots-clés
- New vaccine introduction
Régions de l'OMS
- Région de l'Asie du Sud-Est
